Sutro Biopharma to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Sutro Biopharma (NASDAQ: STRO) announced management participation in multiple investor conferences in early March 2026, including TD Cowen, Leerink Partners, Citizens Life Sciences, and Barclays.

Webcasts of fireside chats at TD Cowen and Citizens will be accessible via the company’s Events & Presentations page, with archived replays available for at least 30 days.

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in several upcoming investor conferences.

Conference Details:

TD Cowen 46th Annual Health Care Conference 
Date: March 2-4, 2026
Location: Boston, MA

Leerink Partners Global Healthcare Conference
Date: March 8-11, 2026
Location: Miami, FL

The Citizens Life Sciences Conference
Date: March 10-11, 2026
Location: Miami, FL

Barclays 28th Annual Global Healthcare Conference
Date: March 10-12, 2026
Location: Miami, FL

Webcasts of the fireside chats at the TD Cowen and Citizens conferences will be accessible through the Events & Presentations page of the Investor Relations section of the Company’s website at www.sutrobio.com. Archived replays will be available for at least 30 days after the event.

About Sutro Biopharma
Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies. For more information, follow Sutro on social media @Sutrobio or visit www.sutrobio.com.

Investor Contact
Emily White
Sutro Biopharma
(650) 823-7681
ewhite@sutrobio.com

Media Contact
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com

FAQ

When will Sutro Biopharma (STRO) present at the TD Cowen 46th Annual Health Care Conference?

Sutro Biopharma will participate at TD Cowen from March 2–4, 2026. According to the company, management will take part in investor sessions and a webcasted fireside chat accessible on the Events & Presentations page of the investor website.

Which Sutro Biopharma (STRO) events will be webcast during March 2026 conferences?

Webcasts will cover fireside chats at TD Cowen and Citizens conferences. According to the company, those webcasts will be available on the Events & Presentations page, with archived replays posted for at least 30 days after each event.

Where and when will Sutro Biopharma (STRO) attend the Miami conference week in March 2026?

Sutro management will attend multiple Miami events March 8–12, 2026, including Leerink Partners, Citizens Life Sciences, and Barclays. According to the company, management participation spans March 8–12 with sessions across those conferences in Miami, FL.

How long will Sutro Biopharma (STRO) archived conference replays remain available online?

Archived replays will remain available for at least 30 days after each event. According to the company, webcasts and replays are posted to the Events & Presentations page on the investor relations website for investor access.

How can investors watch Sutro Biopharma (STRO) conference presentations and replays?

Investors can stream webcasts and view replays via the company’s Events & Presentations page on its investor relations website. According to the company, selected fireside chats will be webcast and archived there for at least 30 days post-event.